GSK application to expand use of Nucala for COPD accepted for review by EMA Ruchika Sharma25 March 2025 1:30 PM ISTIL-5 is a key cytokine (protein) in type 2 inflammation which is an underlying driver in many diseases.
GSK Nucala application for COPD accepted for review in China Ruchika Sharma23 Feb 2025 12:30 PM ISTGSK plc has announced that the China National Medical Products Administration has accepted for review the new drug application for the use of...
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma4 Jan 2025 1:00 PM ISTLondon: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody...
USFDA accepts GSK submission for use of Nucala in COPD Ruchika Sharma11 Dec 2024 11:30 AM ISTLondon: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the...
GSK announces positive results from phase III trial of Nucala in COPD Ruchika Sharma8 Sept 2024 1:30 PM ISTLondon: GSK plc has announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) a...
GSK Nucala approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma3 Sept 2024 4:19 PM ISTGSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Nucala (mepolizumab), a monoclonal antibody that...
Submit details of adverse events reported: CDSCO Panel Tells GSK on Mepolizumab Powder for Solution for Injection Dr. Divya Colin24 Aug 2024 6:00 PM ISTNew Delhi: In line with the Phase IV clinical trial report of the monoclonal antibody Mepolizumab (Brand Name: Nucala 100 mg) presented by the drug...
GSK Nucala approved in China for use in severe asthma with eosinophilic phenotype Ruchika Sharma12 Jan 2024 11:35 AM ISTLondon: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), as an add-on...
GSK regulatory submission accepted for review by Japanese regulator for Nucala use in adults with chronic rhinosinusitis with nasal polyps Ruchika Sharma3 Sept 2023 12:45 PM ISTLondon: GSK plc has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted for review a supplementary new drug...
Mepolizumab reduces exacerbations and OCS use in severe asthma patients Jacinthlyn Sylvia27 Jan 2023 8:00 PM ISTMepolizumab is an anti-IL-5 mAb approved for use as an add-on treatment in patients with severe eosinophilic asthma.According to a new study published...
Mepolizumab effective in Allergic and Non-Allergic Asthma: Study Dr. Shravani Dali10 Dec 2022 9:30 AM ISTMepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma suggests a new study published in the Annals of Allergy, Asthma and...
Mepolizumab demonstrates high clinical efficacy in both allergic and non-allergic Asthma Dr.Niharika Harsha B1 Dec 2022 10:30 AM ISTA new study revealed that mepolizumab is clinically very effective for the treatment of severe allergic and non-allergic phenotypes of asthma. The...
